<DOC>
	<DOCNO>NCT00863174</DOCNO>
	<brief_summary>Safety bioequivalence SPARC_147709</brief_summary>
	<brief_title>A Bioequivalence Study SPARC_147709 Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Availability entire study period willingness adhere protocol requirement . Diagnosis multiple myeloma eligible receive Doxorubicin liposome 18 year age old No evidence underlie disease ( except multiple myeloma ) History presence significant allergy significant history hypersensitivity idiosyncratic reaction doxorubicin hydrochloride History cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunologic , dermatologic , musculoskeletal , neurological psychiatric disease . History smoking ( ≥ 10 cigarettes/day ) consumption tobacco product ( ≥ 4 chews/day ) . Positive result HIV , HCV , RPR HBsAg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Bio-equivalence</keyword>
</DOC>